Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer -- Ignore unavailable to you. Want to Upgrade?

To: adam hefian who wrote (751)	2/28/1998 3:46:00 PM
From: David Cathcart	Respond to of 1826

Adam, <<Assuming we get a European partner in April,is that going to move MOGN to $12?>> First let me say that trying to guess when MOGN is going to reach a certain point is just that: guessing. Having said that, I think April might be a little soon to expect the European deal; my estimate is sometime between April and June. Assuming it happens, the European deal for MGI-114 brings a lot with it: a pile of money, a high profile endorsement of the drug's potential, and the concurrent events of phase II and the involvement of the NCI. Combine that with Salagen in active promotion for Sjogren's and a MOGN share should be a lot more valuable. When the dust settles, I'm looking for $10/share but something considerably higher is not out of the question. Now, it's my turn to ask you questions. At what price per share will you say you are happy with your investment in MOGN? At what price will you be ecstatic? At what price will you say it is the best investment you have ever made? I think it's time for you to start thinking about that. :-) David